Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources
Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV
Antibodies, 2019 In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct.
Lili Wang +10 more
doaj +1 more source
Emerging Antibodies in Cancer Therapy
Advanced NanoBiomed Research, 2023 Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal ...
Yaping Sun, Jian Xu
doaj +1 more source
Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. [PDF]
, 2014 Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. It is an intracellular calcium signal transducer that is differentially expressed in many cancers. It signals cells for self-renewal, proliferation, invasion, and survival.
Bonavida, Benjamin, Shvartsur, Anna
core +2 more sources
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
Frontiers in Immunology, 2023 The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia +24 more
doaj +1 more source
Cell-type specific potent Wnt signaling blockade by bispecific antibody. [PDF]
, 2018 Cell signaling pathways are often shared between normal and diseased cells. How to achieve cell type-specific, potent inhibition of signaling pathways is a major challenge with implications for therapeutic development.
Bidlingmaier, Scott +6 more
core +2 more sources
Single-domain antibodies and their formatting to combat viral infections [PDF]
, 2018 Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies +4 more
core +2 more sources
Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. [PDF]
, 2013 Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action.
Duerr, Harald +12 more
core +3 more sources
Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies [PDF]
, 2013 Background Since most glioblastomas express both wild-type EGFR and EGFRvIII as well as HER2/neu, they are excellent targets for activated T cells (ATC) armed with bispecific antibodies (BiAbs) that target EGFR and HER2.
A Formentini +51 more
core +4 more sources
In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
Molecular Therapy: Methods & Clinical Development, 2017 Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection, necessitating new therapeutic approaches. The T cell response can clear HBV during acute infection, and the adoptive transfer of antiviral T cells during bone ...
Robert L. Kruse +6 more
doaj +1 more source